Plain-English translation of NCT05242315 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 4 โ The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After a liver transplant, patients need to take medication to prevent their body from rejecting the new organ. This trial is testing a new formulation of Envarsus, an anti-rejection medication that you take once a day instead of twice a day. The researchers want to see if this new version is safer and causes fewer side effects โ especially kidney damage and nerve problems โ compared to the standard medication.
The standard anti-rejection medication after liver transplant can damage the kidneys and cause nerve damage in up to 25% of patients, which can affect how long they survive. This medication may work better because it doesn't create the same high peaks in your bloodstream, which is where many of the side effects come from.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would be randomly assigned to take either the new once-daily medication or the standard twice-daily version. You will attend follow-up visits at the University of Alberta where your doctors will monitor your kidney function, check for side effects like tremors or nerve problems, and measure metabolic changes. The study will track how well your new liver is working and how you're doing overall compared to people taking the standard medication.
AI-generated summary from trial data ยท Oct 3, 2026 ยท Not medical advice
Canada